Results from a prospective observational study of men with premature ejaculation treated with dapoxetine or alternative care: The PAUSE study

Abstract Background Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. Objective To characterize the safety profile of dapoxetine in PE treatment and to report the incidence, severity, and type of adverse events. Design, setting, and participants We conducted a 12-wk, open-label, observational study with a 4-wk, postobservational contact. A total of 10 028 patients were enrolled, with 6712 patients (67.6%) treated with dapoxetine 30–60mg (group A)and 3316 (32.4%) treated with alternative care/nondapoxetine (group B). …

COMPLICANZE DELL'OSTEONECROSI DEI MASCELLARI ASSOCIATE A TERAPIA CON BIFOSFONATI: ASPETTI TC ED RM

COMPUTED TOMOGRAPHY AND IMAGING FINDINGS OF CHRONIC OSTEOMYELITIS OF THE JAW.